207 related articles for article (PubMed ID: 23010502)
21. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
22. Clinical Significance of VEGF-A and Microvessel Density in Diffuse Large B-Cell Lymphoma and Low-Grade Follicular Lymphoma.
Shahini L; Gašparov S; Petruševska G; Manxhuka Kerliu S; Veselaj F; Kurshumliu F; Kavaja F
Acta Clin Croat; 2017 Dec; 56(4):588-593. PubMed ID: 29590710
[TBL] [Abstract][Full Text] [Related]
23. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.
Cardoso CC; Auat M; Santos-Pirath IM; Rudolf-Oliveira RCM; da Silva JP; Lange BG; Siegel D; de Moraes ACR; Del Moral JAG; Santos-Silva MC
Cytometry B Clin Cytom; 2018 May; 94(3):451-458. PubMed ID: 28509416
[TBL] [Abstract][Full Text] [Related]
24. Bcl-2 gene rearrangement in Jordanian follicular and diffuse large B-cell lymphomas.
Almasri NM; Al-Alami J; Faza M
Saudi Med J; 2005 Feb; 26(2):251-5. PubMed ID: 15770300
[TBL] [Abstract][Full Text] [Related]
25. Investigating the inequalities in route to diagnosis amongst patients with diffuse large B-cell or follicular lymphoma in England.
Smith MJ; Fernandez MAL; Belot A; Quartagno M; Bonaventure A; Majano SB; Rachet B; Njagi EN
Br J Cancer; 2021 Oct; 125(9):1299-1307. PubMed ID: 34389805
[TBL] [Abstract][Full Text] [Related]
26. Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians.
Kleinstern G; Abu Seir R; Perlman R; Khatib A; Abdeen Z; Elyan H; Nirel R; Amir G; Ramlawi A; Sabatin F; Boffetta P; Dann EJ; Kedmi M; Ellis M; Nagler A; Ben Yehuda D; Paltiel O
PLoS One; 2017; 12(2):e0171709. PubMed ID: 28196110
[TBL] [Abstract][Full Text] [Related]
27. B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS.
Wang SS; Vajdic CM; Linet MS; Slager SL; Voutsinas J; Nieters A; Casabonne D; Cerhan JR; Cozen W; Alarcón G; Martínez-Maza O; Brown EE; Bracci PM; Turner J; Hjalgrim H; Bhatti P; Zhang Y; Birmann BM; Flowers CR; Paltiel O; Holly EA; Kane E; Weisenburger DD; Maynadié M; Cocco P; Foretova L; Breen EC; Lan Q; Brooks-Wilson A; De Roos AJ; Smith MT; Roman E; Boffetta P; Kricker A; Zheng T; Skibola CF; Clavel J; Monnereau A; Chanock SJ; Rothman N; Benavente Y; Hartge P; Smedby KE
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1103-1110. PubMed ID: 35244686
[TBL] [Abstract][Full Text] [Related]
28. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies.
Kane EV; Roman E; Becker N; Bernstein L; Boffetta P; Bracci PM; Cerhan JR; Chiu BC; Cocco P; Costas L; Foretova L; Holly EA; La Vecchia C; Matsuo K; Maynadie M; Sanjose S; Spinelli JJ; Staines A; Talamini R; Wang SS; Zhang Y; Zheng T; Kricker A
Ann Oncol; 2012 Sep; 23(9):2362-2374. PubMed ID: 22786757
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
30. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.
Jelicic J; Balint MT; Jovanovic MP; Boricic N; Micev M; Stojsic J; Antic D; Andjelic B; Bila J; Balint B; Pavlovic S; Mihaljevic B
Pathol Oncol Res; 2016 Jul; 22(3):567-77. PubMed ID: 26750138
[TBL] [Abstract][Full Text] [Related]
31. Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality.
Mansoor A; Kamran H; Rizwan H; Akhter A; Roshan TM; Shabani-Rad MT; Bavi P; Stewart D
Hematol Oncol; 2024 Jan; 42(1):e3225. PubMed ID: 37795760
[TBL] [Abstract][Full Text] [Related]
32. Glyphosate use and associations with non-Hodgkin lymphoma major histological sub-types: findings from the North American Pooled Project.
Pahwa M; Beane Freeman LE; Spinelli JJ; Blair A; McLaughlin JR; Zahm SH; Cantor KP; Weisenburger DD; Punam Pahwa PP; Dosman JA; Demers PA; Harris SA
Scand J Work Environ Health; 2019 Nov; 45(6):600-609. PubMed ID: 31246262
[TBL] [Abstract][Full Text] [Related]
33. N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes.
Cocco P; Zucca M; Sanna S; Satta G; Nonne T; Angelucci E; Gabbas A; Rais M; Malpeli G; Campagna M; Scarpa A; G Ennas M
Hematol Oncol; 2016 Jun; 34(2):79-83. PubMed ID: 25689677
[TBL] [Abstract][Full Text] [Related]
34. Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma.
Frazzi R; Zanetti E; Pistoni M; Tamagnini I; Valli R; Braglia L; Merli F
Leuk Res; 2017 Jun; 57():89-96. PubMed ID: 28324774
[TBL] [Abstract][Full Text] [Related]
35. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.
Gu Y; Shore RE; Arslan AA; Koenig KL; Liu M; Ibrahim S; Lokshin AE; Zeleniuch-Jacquotte A
Cancer Causes Control; 2010 Aug; 21(8):1323-33. PubMed ID: 20373009
[TBL] [Abstract][Full Text] [Related]
36. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Herrera AF; Goy A; Mehta A; Ramchandren R; Pagel JM; Svoboda J; Guan S; Hill JS; Kwei K; Liu EA; Phillips T
Am J Hematol; 2020 Jan; 95(1):18-27. PubMed ID: 31621094
[TBL] [Abstract][Full Text] [Related]
37. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas.
King BE; Chen C; Locker J; Kant J; Okuyama K; Falini B; Swerdlow SH
Mod Pathol; 2000 Nov; 13(11):1219-31. PubMed ID: 11106080
[TBL] [Abstract][Full Text] [Related]
39. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies.
Kane EV; Bernstein L; Bracci PM; Cerhan JR; Costas L; Dal Maso L; Holly EA; La Vecchia C; Matsuo K; Sanjose S; Spinelli JJ; Wang SS; Zhang Y; Zheng T; Roman E; Kricker A;
Ann Oncol; 2013 Feb; 24(2):433-441. PubMed ID: 22967995
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Klanova M; Oestergaard MZ; Trněný M; Hiddemann W; Marcus R; Sehn LH; Vitolo U; Bazeos A; Goede V; Zeuner H; Knapp A; Sahin D; Spielewoy N; Bolen CR; Cardona A; Klein C; Venstrom JM; Nielsen T; Fingerle-Rowson G
Clin Cancer Res; 2019 Aug; 25(15):4634-4643. PubMed ID: 31053601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
